Replimune (REPL) Liabilities and Shareholders Equity (2018 - 2026)

Replimune has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $332.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 39.71% year-over-year to $332.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 30.31% YoY) and the FY2026 annual result came in at $332.4 million, down 39.71% from the prior year.
• Liabilities and Shareholders Equity was little changed at $332.4 million in Q1 2026 per REPL's latest filing, from $333.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $678.6 million in Q4 2022 and troughed at $332.4 million in Q1 2026.
• A 5-year average of $504.8 million and a median of $498.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity surged 40.2% in 2023, then slumped 44.74% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $678.6 million in 2022, then declined by 21.46% to $532.9 million in 2023, then advanced by 13.27% to $603.6 million in 2024, then slumped by 44.74% to $333.6 million in 2025, then declined by 0.36% to $332.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $332.4 million, $333.6 million, and $389.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.